CTTI Project Category: AB Drug Development
Project Status: Current
As a society, we urgently need new types of antibiotic drugs because many bacteria have developed resistance to one or more existing antibiotics. At the same time, fewer drug companies are working on bringing new antibiotics to market. That’s because antibiotic trials are complicated and expensive, and there is little economic incentive to develop drugs that are usually taken for short periods of time rather than long term. In particular, drug trials testing new antibiotics designed to treat bacterial pneumonia acquired as a result of a hospital stay or in association with a ventilator are notoriously complicated, lengthy, and expensive.
The goal of this project is to identify barriers and seek solutions for the successful conduct of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) trials.
Most Visited Pages
CTTI encourages the use of all materials listed on this site in the pursuit of improving the clinical trials enterprise. Our recommendations, tools, meeting summaries, and more are available to the public for free. We do ask that you acknowledge the source whenever using or referencing CTTI materials. Read our Citation Policy here.